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

Genetic variation in the IFNL3–IFNL4 (interferon-3–
interferon-4) region is associated with hepatic inflammation 
and fibrosis–4. Whether IFN-3 or IFN-4 protein drives 
this association is not known. We demonstrate that hepatic 
inflammation, fibrosis stage, fibrosis progression rate,  
hepatic infiltration of immune cells, IFN-3 expression, and 
serum sCD63 levels (a marker of activated macrophages)  
are greater in individuals with the IFNL3–IFNL4 risk haplotype 
that does not produce IFN-4, but produces IFN-3.  
No difference in these features was observed according to 
genotype at rs7648444, which encodes a substitution at 
position 70 of the IFN-4 protein and reduces IFN-4  
activity, or between patients encoding functionally defective 
IFN-4 (IFN-4–Ser70) in comparison to those encoding  
fully active IFN-4–Pro70.


 The two proposed functional 
variants (rs36823485 and rs480327)5,6 were not superior 
to the discovery SNP rs2979860 with respect to liver 
inflammation or fibrosis phenotype.


 IFN-3 rather than  
IFN-4 likely mediates IFNL3–IFNL4 haplotype–dependent 
hepatic inflammation and fibrosis.
Tissue injury leads to an inflammatory host response that, if sus-
tained, results in excess extracellular matrix deposition and fibrosis7. 
Liver disease is a useful generic model of tissue inflammation and 
Q2
Q3
Q4
fibrosis, with most liver-related adverse outcomes being a conse-
quence of fibrosis7.
The interferon family has a pivotal role in defense against a wide 
variety of pathogens, and inflammation constitutes an essential part 
of this response8. In the liver, type Ш interferons (IFN-λ) have a pri-
mary antiviral role9,10 and constitute the dominant interferon sub-
class produced during hepatitis C virus (HCV) infection11,12. There 
is now unequivocal genetic and functional evidence that IFN-λ has 
a substantial influence on hepatic inflammation and fibrosis risk, 
with multiple reports demonstrating that SNPs in the IFNL3–IFNL4 
region, originally discovered through genome-wide association stud-
ies (GWAS) as a predictor of HCV clearance13–16, are a strong predic-
tor of risk1–4. IFN-λ levels are elevated in patients with chronic liver 
disease17 and correlate with inflammation and fibrosis markers4,18. 
IFN-λ also directly activates a positive feedback inflammatory loop 
in cell culture models of HCV19. Further, whereas expression of type 
I and II interferon receptors is impaired during HCV infection and in 
advanced liver disease, IFN-λ receptor expression is unaltered20,21.
IFN-λ4 is the newest member of the IFN-λ family, with rs368234815 
in the IFNL4 gene upstream of IFNL3 controlling the generation of 
IFN-λ4 protein5. The rs368234815[∆G] allele in high linkage dis-
equilibrium (LD) with rs12979860[T] is characterized by expression 
of IFN-λ4 and is implicated in reduced HCV clearance5 (Fig. 1). 
The same allele is associated with lower baseline and inducible 
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 
haplotype–dependent hepatic inflammation and fibrosis
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expression of IFNL3 mRNA in humans (liver biopsies, serum, and 
peripheral blood mononuclear cells (PBMCs))14,15,22–24, in vitro25,26, 
and in chimeric mice27, although two reports have failed to demon-
strate this13,28. However, IFN-λ3 protein levels are consistently lower 
with these alleles23,25,29–31, including in vitro. One study has suggested 
that IFN-λ3 levels are a better predictor of viral clearance than SNPs 
in the IFNL3–IFNL4 region26; previous studies are summarized in 
Supplementary Table 1.
Whether IFN-λ4 or IFN-λ3 activity drives the functional asso-
ciation with hepatic inflammation and fibrosis1–3 is unknown. 
Addressing this question is challenging, owing to extremely low (and 
often undetectable) hepatic IFN-λ4 expression32–34 and because the 
IFNL4 region is absent from rat and mouse genomes.

 Recently, on 
the basis of the co-inheritance pattern of a substitution in IFNL4 at 
rs117648444 and rs368234815 genotype, we provided a clue suggest-
ing that genetic information can be used to test, in a human context, 
the role of IFN-λ4 activity in mediating hepatic inflammation and, 
thereby, fibrosis35.
We tested for association of IFN-λ4 and IFN-λ3 activity with 
hepatic inflammation and fibrosis in a well-characterized cohort of 
1,923 Caucasian HCV-infected patients.

 In addition to rs12979860, 
we assessed IFNL4 rs117648444 and the two potential functional 
SNPs IFNL4 rs368234815 and rs4803217 in the 3′ UTR of IFNL3 that 
influences IFNL3 mRNA stability6,31. The IFNL3 and IFNL4 genes 
and genetic variants are schematically presented in Figure 1. The 
association analysis was carried out for three pairwise combinations 
of phenotype status: significant hepatic inflammation (cases) versus 
mild inflammation (controls), significant hepatic fibrosis (cases) ver-
sus mild fibrosis (controls), and fast fibrosis progression rate (FPR) 
(cases) versus slow FPR (controls). Histological definitions and patient 
phenotypes are provided in the Online Methods, and clinical char-
acteristics are shown in Supplementary Table 2. The characteristics 
of the FPR subcohort with a known duration of infection (n = 1,003) 
were generally similar among subjects included and not included in 
the subanalysis. The genotype distributions of IFNL3 and IFNL4 vari-
ants (rs4803217, rs368234815, rs117648444, and rs12979860) were in 
Hardy–Weinberg equilibrium (Supplementary Table 2); LD values 
between variants are displayed in Supplementary Table 3 and were 
consistent with previous reports5,6,36.
On the basis of the strong LD between rs4803217 and rs368234815 
(r2 = 0.93) and LD of these SNPs with rs12979860 (r2 = 0.93 and 
0.96, respectively), association tests for the functional variants gave 
results similar to those for rs12979860 and showed strong associa-
tion with the three phenotypes: significant inflammation (P < 4.7 ×  
10−14, for all three SNPs), significant fibrosis (P < 2.6 × 10−6, for 
all three SNPs), and fast FPR (P < 5.5 × 10−4, for all three SNPs).

  
Associations remained significant after adjustment for sex, age, body 
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Figure 1 Schematic of the IFNL3 and IFNL4 genes and genetic variants.
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mass index (BMI), recruitment center, liver enzymes, diabetes mel-
litus, HCV genotype, and alcohol intake (Table 1). For confirmation, 
fibrosis progression was assessed by Cox proportional-hazards model 
to address the concern that FPR might not be constant37; similar find-
ings were obtained (Fig. 2).
In contrast, we observed no association of rs117648444 with any of 
the three phenotypes (Table 1). rs117648444 was also not associated 
with an increased hazard of progression to significant fibrosis (Fig. 2). 
Similar results were obtained in linear regression (considering the 
phenotypes as continuous variables) (estimate = 0.034, P = 0.2 and 
estimate = 0.019, P = 0.5 for inflammation and fibrosis, respectively) 
and when adopting other genetic models (additive or recessive).

We next tested for association of IFN-λ4 activity with inflamma-
tion and fibrosis phenotypes based on co-inheritance of rs368234815 
and rs117648444. The combination frequency distribution 
(Supplementary Table 4) and associated haplotype (Supplementary 
Table 5) and diplotypes (Supplementary Table 6) were concordant 
with earlier reports5,35.

 There were four haplotypes: TT/G (60%), 
which does not produce IFN-λ4; ∆G/G (29%), which produces 
IFN-λ4-Pro70; ∆G/A (10%), which produces functionally defective 
IFN-λ4-Ser70; and TT/A (0.6%), which does not produce IFN-λ4.

  
The diplotypes were classified according to their ability to produce fully 
active or functionally defective IFN-λ4: those producing (i) no IFN-
λ4 (n = 688; 35.8%), (ii) IFN-λ4–Pro70 (only IFN-λ4–Pro70 or both 
IFN-λ4–Pro70 and IFN-λ4–Ser70 (n = 961; 50%), and (iii) exclusively 
functionally defective IFN-λ4–Ser70 (n = 274; 14.2%). Group 
Q8
Q9
Q10
(ii) comprised 854 patients (88.9%) producing only IFN-λ4–Pro70 
and 107 (11.1%) producing both IFN-λ4–Pro70 and IFN-λ4–Ser70.
No association of IFN-λ4 activity with clinical, viral, or biochemi-
cal covariates was found. We analyzed inflammation and fibrosis 
phenotypes of patients producing IFN-λ4–Ser70 alone versus those 
producing both IFN-λ4–Pro70 and IFN-λ4–Ser70 versus those 
not producing IFN-λ4. As expected, patients not producing IFN-λ4 
(but producing increased amounts of IFN-λ3) had higher odds for 
all inflammation and fibrosis phenotypes when compared to patients 
producing any IFN-λ4 (Table 2). In analysis excluding subjects not 
producing IFN-λ4 (to specifically assess the role of the p.Pro70Ser 
substitution), there was no difference between those producing fully 
active IFN-λ4 (IFN-λ4–Pro70 alone or both IFN-λ4–Pro70 and IFN-
λ4–Ser70) and those producing defective IFN-λ4–Ser70 (Table 2). 
This was confirmed using Cox proportional-hazards models (Fig. 2). 
Similar results were observed when the 107 patients producing both 
IFN-λ4–Pro70 and IFN-λ4–Ser70 were excluded. Although an analy-
sis based on repeat biopsies in large cohorts with a wide time interval 
between biopsies would have been ideal, this was not possible given 
ethical and logistic concerns and is a limitation of the present study.
Collectively, these data suggest that, in contrast to viral clearance, 
IFN-λ4 activity as measured by the relative effects of the Pro70- and 
Ser70-encoding alleles, does not contribute to hepatic inflammation 
or fibrosis phenotypes. For the former, virus-triggered weak hepatic 
expression of IFN-λ4 (which is inefficiently secreted and not abun-
dant)32–34 likely induces baseline interferon-stimulated gene expres-
sion and inhibits further induction of these genes through institution 
of interferon-based therapy.

 However, this is less likely to sustain a 
proinflammatory state.

 IFN-λ4 has antiviral and proinflammatory 
effects in vitro32,34,38, making it unlikely that it has anti-inflamma-
tory effects.
A crucial role has been established for infiltrating immune cells in 
the progression of hepatic inflammation and fibrosis39. Inflammatory 
cytokines released from these cells perpetuate inflammation as well 
as activating hepatic stellate cells39. Therefore, to gain insights into 
how the risk haplotype associates with inflammation, we interro-
gated the profiles of T cell and macrophage markers (CD3, CD8, and 
CD163) that are known to be relevant to inflammation and fibrosis39 
in the liver lobules and portal areas of 90 patients segregated accord-
ing to IFNL3–IFNL4 haplotype and IFN-λ4 activity (characteristics 
are given in Supplementary Table 7). Patients with the risk hap-
lotype had increased numbers of CD3+CD8+ T cells

 and CD163+ 
macrophages (Fig. 3). In contrast, no difference in immune cell num-
bers was noted according to IFN-λ4 activity (IFN-λ4–Pro70 versus 
IFN-λ4–Ser70) or according to IFNL4 rs117648444 genotype. 
Consistent with these findings, in a subset of 506 patients (characteristics 
summarized in Supplementary Table 8) who matched the overall 
cohort with respect to age, sex, and BMI, the levels of sCD163, a 
Q11
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Figure 2 Univariate Cox regression analysis of association of IFNL3  
and IFNL4 variants or IFN-λ4 activity with fibrosis progression.


  
(a–c) Univariate Cox regression analysis of the effect of rs12979860 (a), 
rs117648444 


(b), and IFN-λ4 activity (c) on the cumulative probability 
of progression to significant fibrosis (≥F2) in 1,003 patients with a known 
duration of HCV infection.


 Data for SNPs rs12979860 and rs117648444 
are shown for a dominant model. IFN-λ4 activity analysis is based on 
comparison of patients producing a fully functional IFN-λ4 protein  
(IFN-λ4–Pro70) or both IFN-λ4–Pro70 and IFN-λ4–Ser70 to those 
producing only functionally defective IFN-λ4–Ser70. Similar results  
were observed in multivariate Cox regression analysis after adjusting for 
clinical covariates (age, sex, BMI, HCV genotype, recruitment center, and 
liver enzymes). HR, hazards ratio; CI, confidence interval.


 
Q28
Q38
Q29
Q30
table 2 Association between IFN-l4 activity and hepatic inflammation, fibrosis, and fibrosis progression
Significant inflammation Significant fibrosis Fast FPR
IFN-l4 activity OR 95% CI P value OR 95% CI P value OR 95% CI P value
No IFN-λ4 Reference Reference Reference
IFN-λ4–Ser70 alone 0.462 0.34–0.63 5 × 10−7 0.708 0.535–0.939 0.01 0.702 0.5–0.92 0.01
IFN-λ4–Pro70 or IFN-λ4–Pro70 + IFN-λ4–Ser70 0.419 0.34–0.52 1.4 × 10−12 0.623 0.444–0.783 0.006 0.651 0.492–0.893 0.01
IFN-λ4–Pro70 and IFN-λ4–Pro70 + IFN-λ4–Ser70 Reference Reference Reference
IFN-λ4-Ser70 alone 0.874 0.648–1.17 0.3 0.839 0.642–1.09 0.2 0.87 0.51–0.93 0.4
OR, odds ratio; FPR, fibrosis progression rate. Odds ratios are provided with 95% confidence intervals. Analysis of association with IFN-λ4 activity is based on comparison of 
patients producing a fully functional IFN-λ4 protein (IFN-λ4–Pro70) or both IFN-λ4–Pro70 and IFN-λ4–Ser70 with those producing only functionally defective (IFN-λ4–Ser70) 
protein.


 Liver biopsy data are according to Metavir score.


 Cases with inflammation stage ≥A2 were classified as having significant inflammation, and those with fibrosis stage ≥F2 
were classified as having significant fibrosis. FPR was calculated by taking the ratio between the fibrosis stage and the estimated disease duration (in years); FPR greater than or 
equal to the median rate (0.0714 fibrosis units/year) was used as the cutoff to define fast FPR.


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macrophage activation marker associated with hepatic inflammation 
and fibrosis in chronic hepatitis C40, were higher in subjects with the 
rs12979860 risk genotype (Fig. 3); this association remained significant 
in multivariate analysis (estimate = 0.092, standard error (SE) = 0.009; 
P = 0.03).

 Similar results were observed for rs368234815 and 
rs4803217 (Supplementary Fig. 1). There was no difference accord-
ing to rs117648444 genotype (Supplementary Fig. 1) or IFN-λ4 
activity (Fig. 3).
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Figure 3 Correlation of IFNL3 and IFNL4 variants and inflammatory cells in liver biopsy specimens with serum sCD163 levels. (a–i) Immunohistochemical 
staining of liver biopsy specimens. Inflammatory cells are more numerous in the portal tracts and liver lobules of patients with the CC genotype at 
rs12979860 than in patients with the CT/TT genotype, while there was no difference according to IFN-λ4 activity. (a–c) Representative images are shown 
(original magnifications, 200×). (d–i) The x axis shows genotype at rs12979860 using the dominant model of inheritance (CC = 30, CT/TT = 60) (d–f) or 
IFN-λ4 activity based on comparison of patients producing a fully functional IFN-λ4 protein (IFN-λ4–Pro70) or both IFN-λ4–Pro70 and IFN-λ4–Ser70 as 
compared to those producing only functionally defective IFN-λ4–Ser70 protein (Pro70 = 30, Ser70 = 30) (g–i). The y axis shows the numbers of cells per 
unit area. We tested the difference in the median values among the genotypes using two-tailed Mann–Whitney U tests performed with a false discovery  
rate (FDR) procedure for generating corrected P values to adjust for multiple testing. (j,k) Association between rs12979860 genotype (j) and IFN-λ4 
activity (k) and serum sCD163 levels in 506 patients with chronic hepatitis C. The x axis shows genotype at rs12979860 (CC = 223, CT/TT = 283) (j) or 
IFN-λ4 activity (Pro70 = 188, Ser70 = 54) (k), and the y axis shows sCD163 expression level (mg/ml)


 by ELISA. The number of samples tested in each 
group is shown in parentheses. Each group is shown as a box plot, and the median values are shown as thick horizontal lines. The box covers the 25th to 
75th percentiles.


 We plotted the box plots using GraphPad Prism 7.
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Immune cells are major producers of IFN-λ3 (ref. 25); in con-
trast, IFN-λ4 production has not been demonstrated in these cells.

  
Hence, greater immune cell infiltration in the livers of patients with 
the risk haplotype should result in higher production of IFN-λ3 by 
these as well as other cell types in liver. To evaluate this hypothesis, 
we quantified absolute levels of IFNL3 transcript by ultrasensitive 
droplet digital PCR (ddPCR) in 115 liver biopsies from patients 
with HCV. As expected, subjects with the rs12979860 risk genotype 
had significantly higher IFNL3 hepatic expression, consistent with 
earlier reports14,15,22–24.

 Notably, IFNL3 expression was elevated in 
patients with significant inflammation and fibrosis when compared 
to patients with no or mild inflammation and fibrosis, respectively 
(Fig. 4). This suggests that the IFN-λ3 produced in greater amounts 
in patients with the risk haplotype (who are also non-producers of 
IFN-λ4) is likely to mediate the association with hepatic inflamma-
tion and fibrosis.
In conclusion, IFN-λ3, but not IFN-λ4, is likely to be the major 
IFN-λ subclass mediating hepatic inflammation and fibrosis progres-
sion in patients with chronic hepatitis C. The effect is likely through 
increased inflammatory cell infiltration in the liver.

MeThoDS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version 
of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Patient cohort. The study comprised 1,923 consecutive Caucasian Europeans 
with chronic hepatitis C from the International Liver Disease Genetics 
Consortium (ILDGC).


 All patients with serum positivity for HCV RNA and 
of European descent at the participating centers who had a liver biopsy 
with scoring for fibrosis stage and disease activity before treatment between 
1999 and 2011 were included if they had available genomic DNA. Patients 
were excluded if they had evidence of other concomitant liver diseases, 
including co-infection by HIV or hepatitis B virus (HBV), autoimmune hep-
atitis, Wilson’s disease, α-1 antitrypsin deficiency, or hemochromatosis, by 
standard tests.


Ethics approval was obtained from the Human Research Ethics Committees 
of the Sydney West Local Health District and the University of Sydney. All 
other sites had ethics approval from their respective ethics committees. Written 
informed consent for genetic testing was obtained from all participants.
Clinical and laboratory assessment. The following data were collected at the 
time of liver biopsy from all patients: sex, age, ancestry, recruitment center, 
alcohol intake, BMI, and findings from routine laboratory tests. BMI was 
calculated as weight divided by the square of height (kg/m2).
Methods to estimate the duration of infection. Fibrosis progression was 
examined in 1,003 patients with chronic hepatitis C who had a reliable esti-
mated duration of infection as previously reported2. Briefly, for subjects with 
a history of injection drug use (n = 663), the time of infection was estimated 
using the reported “first year of injection.” For patients with a history of blood 
transfusion (n = 244), the onset of infection was assumed to be the year of 
transfusion. For patients with a history of occupational exposure (n = 96), the 
onset of infection was assumed to be the first year of needle stick exposure. 
The duration of infection was calculated by subtracting estimated age at the 
time of infection from age at biopsy.
Genotyping. Genotyping for the rs12979860 and rs368234815 SNPs was 
undertaken using the TaqMan SNP genotyping allelic discrimination method 
(Applied Biosystems). Genotyping for rs4803217 and rs117648444 was con-
tracted to the Australian Genome Research Facility (AGRF; Queensland, 
Australia). Samples were genotyped using the Sequenom MassARRAY system 
and iPLEX Gold chemistry. Part of the genotyping for these SNPs (n = 1,130) 
was undertaken using the TaqMan SNP genotyping allelic discrimination 
method (Applied Biosystems) and the Competitive Allele-Specific PCR 
(KASP) system (LGC Genomics), respectively. Genotyping was performed 
on the StepOne RT system, and results were analyzed with StepOne software 
(Applied Biosystems). All genotyping was undertaken with blinding to clini-
cal variables.
Liver histopathology. Liver histopathology was scored according to 
METAVIR41. Fibrosis was staged from F0 (no fibrosis) to F4 (cirrhosis). 
Necroinflammation (A) was graded as A0 (absent), A1 (mild), A2 (moderate), 
or A3 (severe). All biopsies had a minimum of 11 portal tracts, and inadequate 
biopsies were excluded. The agreement among pathologists was studied previ-
ously and was good for METAVIR staging (κ = 77.5) using κ statistics42.
Immunohistochemistry. Immunohistochemistry was undertaken in a well-
characterized subcohort with liver biopsy sections available for analysis (n = 90). 
Patients with additional risk factors for liver fibrosis other than chronic 
hepatitis C, that is, those with diabetes, significant or heavy alcohol intake 
(>50 g/d), or moderate or severe steatosis, were excluded. Sections (4 µm 
thick) were cut from formalin-fixed, paraffin-embedded (FFPE) specimens, 
and staining was performed on a Ventana Roche BenchMark ULTRA Slide 
Staining System according to standard protocols. Slides were deparaffinized 
in EZprep (Ventana) and washed with Ventana reaction buffer, and HIER was 
performed with Ventana ultraCC1 at 95–100 °C for between 32 and 64 min, 
according to specific protocols. Slides were incubated at 36 °C with primary 
antibodies against CD3 and CD8 (Ventana; prediluted) and against CD163 
(CellMarque; 1:50 and 1:1500 dilutions, respectively).


 Detection was car-
ried out using Ventana optiview (CD163) and Ventana ultraview (CD3 and 
CD8) with DAB as the chromogen. Slides underwent scanning and digital 
Q18
Q19
Q20
microscopy using the Aperio ScanScope System (Aperio). For each biopsy and 
for each cell marker, a portion of the tissue was measured, the area of included 
portal tracts and fibrous tissue was measured, and the corresponding liver 
immune cell content was manually quantified in portal tracts and in lobular 
parenchyma, all using Aperio ImageScope software.


 Inflammatory cell density 
in portal areas/areas of fibrous stroma and in lobular parenchymal regions of the 
liver was then calculated (cells/mm2). Clusters of CD163+ cells were regarded 
as foci with two or more CD163+ confluent cells with identifiable nuclei. Singly 
distributed macrophages were not counted. Individual CD163+ cells could not 
be distinguished in portal tracts, and reliable counting was not possible.
Determination of plasma sCD163 levels by sandwich ELISA. Plasma 
sCD163 levels were measured by ELISA using a BEP-2000 ELISA analyzer 
(Dade Behring). Measurements were performed in duplicate40. The limit of 
detection (lowest standard) was 6.25 µg/l.
RNA extraction and cDNA synthesis. Total RNA was isolated from snap-
frozen liver biopsies using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions from 115 patients who underwent liver biopsy 
at Westmead Hospital, Sydney. Inclusion criteria were availability of stored 
liver tissue and no additional risk factors for hepatic fibrosis, that is, diabetes, 
obesity (BMI >30 kg/m2), or significant alcohol intake (>50 g/d). RNA quality 
and concentration were assessed using an Agilent 2100 Bioanalyzer (Agilent 
Technologies). cDNA was prepared using qscript (Quanta Biosciences) on a 
MasterCycler Gradient 5331 (Eppendorf).
Droplet digital PCR. Absolute quantification of IFNL3 transcripts was per-
formed by ddPCR analysis according to the manufacturer’s instructions. Briefly, 
reactions were performed in a 20-µl reaction volume that consisted of 10 µl of 
QX200 ddPCR EvaGreen Supermix (Bio-Rad), 5 µl of gene-specific primer, 
and 5 µl of cDNA sample. Droplet formation was carried out using a QX100 
droplet generator (Bio-Rad). Each sample was partitioned into an emulsion of 
approximately 20,000 uniformly sized nanoliter droplets. The droplet emulsion 
was transferred to a 96-well plate (Eppendorf) and heat-sealed at 180 °C for 
5 s with foil. Thermal cycling was performed using the C1000 Touch Thermal 
Cycler (Bio-Rad) according to the manufacturer’s cycling conditions. Each plate 
was incubated at 95 °C for 5 min, followed by 40 cycles of 95 °C for 30 s and 
60 °C for 1 min, with a final 10-min incubation at 98 °C. At least two negative- 
control wells with no cDNA template were included in every run. After PCR, 
the RNA content of the droplets was quantified using the QX200 Droplet 
Reader (Bio-Rad). ddPCR data were analyzed using QuantaSoft software. The 
fractions of positive and negative droplets were determined, and data were 
fitted to Poisson statistics and the background was corrected on the basis of 
the data for the no-template control. Absolute transcript levels were initially 
presented as copies per microliter and converted to copies per nanogram of 
RNA on the basis of the input amount of RNA.
Sample size calculation and linkage disequilibrium. We examined the LD 
of IFNL3 and IFNL4 variants (rs12979860, rs4803217, rs368234815, and 
rs117648444) by calculating the correlation coefficient (r2) using Haploview 
software (version 4.2)43. Using the CaTS power calculator for genetic associa-
tion studies44 and assuming a minor allele frequency (MAF) for rs117648444 
of 0.11, our cohort had 97% power for the dominant genetic model and 94% 
power for the additive genetic model for liver inflammation. For analysis, 
the IFNL3 and IFNL4 variants (rs12979860, rs4803217, rs368234815, and 
rs117648444) were coded in a dominant genetic model, which best fit the 
data and as previously shown2,35.
Statistical analysis. Results are expressed as mean ± s.d. or as median and 
range or number (percentage) of patients.


 Student’s t test or non-parametric 
tests, i.e., Wilcoxon–Mann–Whitney U tests or Kruskal–Wallis tests, were 
used to compare quantitative data, as appropriate. χ2 tests and Fisher exact 
tests were used for comparison of frequency data and to evaluate the rela-
tionships between groups. All tests were two-tailed, and P values <0.05 were 
considered significant.
Multivariate logistic regression analysis with backward elimination was 
undertaken to test independent associations of the IFNL3 and IFNL4 variants 
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with (i) inflammation, (ii) fibrosis, and (iii) fibrosis progression. Because of 
the high LD among IFNL3 and IFNL4 variants, multiple multivariate mod-
els were adopted incorporating biologically relevant covariates associated 
with risk of liver disease progression (sex, age, BMI, recruitment center, liver 
enzymes, diabetes mellitus, HCV genotype, and alcohol intake). HCV RNA 
levels were log transformed before entry into the model. Hepatic inflam-
mation was dichotomized as mild (METAVIR score A0–A1) or significant 
(METAVIR score A2–A3), and fibrosis was dichotomized as mild (METAVIR 
stage F0–F1) or significant (METAVIR stage F2–F4). FPR was calculated by 
taking the ratio between the fibrosis stage and the estimated disease duration 
(in years)2. Patients were stratified into two groups according to the median 
rate (0.0714 fibrosis units/year), which was used as a cutoff. Final models were 
assessed using the Hosmer–Lemeshow goodness-of-fit and Pearson goodness-
of-fit tests. Results are expressed as β values ± s.e.m. or odds ratios with 95% 
confidence intervals, as appropriate.
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